{"id":10273,"date":"2026-07-15T11:58:17","date_gmt":"2026-07-15T09:58:17","guid":{"rendered":"https:\/\/cleanpeptides.eu\/cagrilintide-doseringsguide\/"},"modified":"2026-07-15T11:58:17","modified_gmt":"2026-07-15T09:58:17","slug":"cagrilintide-doseringsguide","status":"publish","type":"page","link":"https:\/\/cleanpeptides.eu\/da\/cagrilintide-doseringsguide\/","title":{"rendered":"Cagrilintid doseringsguide"},"content":{"rendered":"<p><em>Kun til forskningsform\u00e5l \u2014 ikke beregnet til menneskelig brug. Clean Peptides giver ingen r\u00e5dgivning om dosering eller brug. Denne guide samler produktinformation og uafh\u00e6ngigt undervisningsmateriale som forskningsreference; den udg\u00f8r ikke l\u00e6gelig r\u00e5dgivning.<\/em><\/p>\n<p><strong>Advarsel \u2014 fors\u00f8gsl\u00e6gemiddel:<\/strong> Cagrilintid (AM833) er IKKE FDA-godkendt. Doseringen her stammer fra publicerede kliniske fors\u00f8g, ikke fra en godkendt indl\u00e6gsseddel.<\/p>\n<h2>Hvad er Cagrilintid?<\/h2>\n<p>Cagrilintid (AM833) er en langtidsvirkende amylin-analog udviklet af Novo Nordisk. Amylin er et naturligt hormon, der frigives sammen med insulin efter m\u00e5ltider og signalerer m\u00e6thed; cagrilintid kopierer det signal i en form, der varer omkring en uge, s\u00e5 \u00e9n ugentlig injektion holder appetitten nedsat. Det unders\u00f8ges alene og kombineret med semaglutid som \u00e9n ugentlig injektion kaldet CagriSema. I fase 3-fors\u00f8get REDEFINE 1 gav CagriSema et v\u00e6gttab p\u00e5 20,4 % efter 68 uger.<\/p>\n<h2>N\u00f8gleegenskaber<\/h2>\n<ul>\n<li>Langtidsvirkende amylin-analog \u2014 kopierer m\u00e6thedshormonet efter m\u00e5ltid; varer ~en uge.<\/li>\n<li>Appetit og m\u00e6thed \u2014 virker p\u00e5 hjernens sultkontrolomr\u00e5der.<\/li>\n<li>Langsommere ventrikelt\u00f8mning \u2014 forl\u00e6nger m\u00e6theden.<\/li>\n<li>CagriSema-kombination \u2014 parret med semaglutid 2,4 mg som \u00e9n ugentlig injektion.<\/li>\n<li>Injektion \u00e9n gang om ugen \u2014 halveringstid ~7\u20138 dage.<\/li>\n<li>Under udvikling \u2014 CagriSema under FDA-vurdering.<\/li>\n<\/ul>\n<h2>S\u00e5dan fastl\u00e6gges doseringen<\/h2>\n<p>Kommer direkte fra kontrollerede fors\u00f8g. Fase 2 monoterapi (Lau et al., Lancet 2021, n=706): dosisafh\u00e6ngigt v\u00e6gttab.<\/p>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Gruppe (ugentlig)<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Gennemsnitligt v\u00e6gttab<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Placebo<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">3,0 %<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Cagrilintid 0,3\u20132,4 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">6,0 % til 9,7 %<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Cagrilintid 4,5 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">10,8 %<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Liraglutid 3,0 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">9,0 %<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Fors\u00f8g<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Population<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">CagriSema<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Placebo<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">REDEFINE 1<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Uden diabetes<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">20,4 %<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">3,0 %<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">REDEFINE 2<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Type 2-diabetes<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">13,7 %<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">3,4 %<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<h2>Doseringsprotokoller<\/h2>\n<p><strong>Cagrilintid alene:<\/strong><\/p>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Periode<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Ugentlig dosis<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Form\u00e5l<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Trin 1<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">0,3 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Indledende tolerance, mave-akklimatisering<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Trin 2<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">0,6 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">F\u00f8rste \u00f8gning<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Trin 3<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">1,2 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">N\u00e6rmer sig det terapeutiske interval<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Vedligeholdelse<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">2,4 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Etableret m\u00e5l (op til 4,5 mg unders\u00f8gt)<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<p><strong>CagriSema (hver komponent):<\/strong><\/p>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Periode<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Hver komponent (ugentlig)<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Varighed<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Trin 1<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">0,25 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Uge 1\u20134<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Trin 2<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">0,5 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Uge 5\u20138<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Trin 3<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">1,0\u20131,7 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Uge 9\u201316<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Vedligeholdelse<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">2,4 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Uge 17+<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<h2>Cagrilintid vs GLP-1-l\u00e6gemidler<\/h2>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Egenskab<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Cagrilintid \/ CagriSema<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Semaglutid<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Tirzepatid<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Mekanisme<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Amylin (+ GLP-1 i CagriSema)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Kun GLP-1<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">GLP-1 + GIP<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">FDA-status<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Under udvikling (under vurdering)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Godkendt<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Godkendt<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">M\u00e5ldosis<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">2,4 mg ugentligt<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">2,4 mg ugentligt<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">15 mg ugentligt<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Maks. v\u00e6gttab (fors\u00f8g)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">20,4 % CagriSema, 10,8 % alene<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">15\u201317 % ved 68 uger<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">22,5 % ved 72 uger<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Halveringstid<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">7\u20138 dage<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">7 dage<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">5 dage<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<h2>Rekonstituering og dosering (med de medf\u00f8lgende 3 mL)<\/h2>\n<p>Hvert Clean Peptides-h\u00e6tteglas leveres med 3 mL bakteriostatisk vand (0,9 % benzylalkohol). Alle tal nedenfor foruds\u00e6tter rekonstituering med de fulde 3 mL. P\u00e5 en standard U-100-insulinspr\u00f8jte er 100 enheder = 1 mL.<\/p>\n<p><strong>Hurtig formel:<\/strong> koncentration = h\u00e6tteglassets styrke \u00f7 3 mL; enheder der skal tr\u00e6kkes = dosis (mg) \u00d7 300 \u00f7 h\u00e6tteglassets styrke (mg).<\/p>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">H\u00e6tteglas (Clean Peptides)<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Koncentration<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">0,6 mg<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">1,2 mg<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">2,4 mg<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">5 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">1,67 mg\/mL<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">36 u<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">72 u<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">144 u<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<p>Opbevar det rekonstituerede produkt i k\u00f8leskab (2\u20138 \u00b0C) og brug det inden for 28-30 dage.<\/p>\n<h2>Dosering efter m\u00e5l<\/h2>\n<ul>\n<li><strong>Maksimalt v\u00e6gttab:<\/strong> CagriSema (2,4 mg + 2,4 mg\/uge): 20,4 % ved 68 uger (uden diabetes), 13,7 % (type 2-diabetes). Optrap begge komponenter parallelt over 16 uger, varighed 68 uger.<\/li>\n<li><strong>Kun amylin:<\/strong> cagrilintid alene (op til 2,4\u20134,5 mg\/uge): op til 10,8 % over 26 uger ved 4,5 mg. Optrapning fra 0,3 mg.<\/li>\n<\/ul>\n<p>CagriSema gav omtrent det dobbelte v\u00e6gttab af cagrilintid alene, men tilf\u00f8jer et andet l\u00e6gemiddel (semaglutid).<\/p>\n<h2>Injektionsguide<\/h2>\n<p>Vask h\u00e6nderne og g\u00f8r materialet klar. Aft\u00f8r h\u00e6tteglassets prop og lad den t\u00f8rre. Tr\u00e6k din dosis op og bank boblerne ud. V\u00e6lg stedet \u2014 nedre mave (2\u20133 cm fra navlen), \u00f8verste l\u00e5r eller bagsiden af overarmen. Rens stedet og lad det t\u00f8rre. Injicer subkutant i en knebet fold ved 45\u00b0. Bortskaf i en kanylebeholder. En gang om ugen, samme dag, skift mellem stederne.<\/p>\n<h2>Behandlingsvarighed<\/h2>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Fase<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Uger<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Beskrivelse<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Titrering<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Uge 1\u201316<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Gradvis \u00f8gning til 2,4 mg, fokus p\u00e5 mave-tarm-tolerance<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Aktivt v\u00e6gttab<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Uge 16\u201368<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Fuld dosis, st\u00f8rstedelen af v\u00e6gttabet sker her<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Vedligeholdelse<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Uge 68+<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Stabilisering, langtidsdata indsamles stadig<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<p>Oph\u00f8r f\u00f8rer typisk til betydelig v\u00e6gt\u00f8gning igen \u2014 planl\u00e6g langtidsbrug, hvis vedligeholdelse er m\u00e5let.<\/p>\n<h2>CagriSema og kombinationer<\/h2>\n<p>CagriSema kombinerer cagrilintid (amylin-analog) og semaglutid 2,4 mg (GLP-1-agonist) i \u00e9n ugentlig injektion og forener to komplement\u00e6re mekanismer til appetitkontrol for et v\u00e6gttab p\u00e5 omtrent det dobbelte af hver komponent alene.<\/p>\n<h2>Sikkerhed, bivirkninger og kontraindikationer<\/h2>\n<p>Fors\u00f8gsl\u00e6gemiddel \u2014 langtids- og sj\u00e6ldne bivirkninger karakteriseres stadig. Mave-tarm (mest almindelige): kvalme (topper under titrering), opkastning (mere sandsynligt ved forceret titrering), diarr\u00e9, forstoppelse, nedsat appetit. Overvejende milde til moderate og forbig\u00e5ende.<\/p>\n<p><strong>Hjerte og blodtryk:<\/strong> cagrilintid 4,5 mg gav ikke klinisk relevant QT-forl\u00e6ngelse; CagriSema s\u00e6nkede blodtrykket i REDEFINE 1 (overv\u00e5g ved brug af blodtryksmedicin).<\/p>\n<p><strong>Forventede kontraindikationer:<\/strong> tidligere pankreatit; galdebl\u00e6resygdom; graviditet\/amning; type 1-diabetes. CagriSema-kombinationen tilf\u00f8jer semaglutids GLP-1-klasseadvarsel (medull\u00e6r thyreoideakr\u00e6ft \/ MEN2 i anamnesen).<\/p>\n<p><strong>Baseline-pr\u00f8ver:<\/strong> fasteblodsukker og HbA1c; udvidet metabolisk panel med leverfunktion; lipidprofil; lipase og amylase; hvilepuls og blodtryk.<\/p>\n<h2>Almindelige fejl<\/h2>\n<ul>\n<li>At starte p\u00e5 fuld m\u00e5ldosis uden titrering.<\/li>\n<li>At antage, at monoterapi giver CagriSema-niveau-resultater (~10 % vs ~20 %).<\/li>\n<li>At behandle cagrilintid som et GLP-1-l\u00e6gemiddel (det er en amylin-analog).<\/li>\n<li>At glemme, at CagriSema indeholder to l\u00e6gemidler.<\/li>\n<li>At forvente sikkerhedsdata som for et godkendt l\u00e6gemiddel.<\/li>\n<li>Rekonstituerings-\/doseringsfejl ved sm\u00e5 doser.<\/li>\n<\/ul>\n<h2>Vigtigste pointer<\/h2>\n<ul>\n<li>Langtidsvirkende amylin-analog \u2014 en anden mekanisme end GLP-1-l\u00e6gemidler.<\/li>\n<li>CagriSema (cagrilintid 2,4 mg + semaglutid 2,4 mg) gav ~20,4 % v\u00e6gttab ved 68 uger.<\/li>\n<li>Cagrilintid alene: op til 10,8 % over 26 uger, bedre end liraglutid 3,0 mg.<\/li>\n<li>SC en gang om ugen, halveringstid ~7\u20138 dage; titrering obligatorisk.<\/li>\n<li>IKKE FDA-godkendt \u2014 CagriSema under FDA-vurdering (afg\u00f8relse forventet i 2026 iflg. offentlig omtale).<\/li>\n<\/ul>\n<h2>Download og relaterede ressourcer<\/h2>\n<p><a href=\"https:\/\/cleanpeptides.eu\/wp-content\/uploads\/2026\/07\/14-Cagrilintide-Dosage-Guide-Clean-Peptides.pdf\">\ud83d\udcc4 Download den fulde PDF-guide<\/a><\/p>\n<p><a href=\"https:\/\/cleanpeptides.eu\/product\/cagrilintide-5-mg\/\">Cagrilintid 5 mg<\/a> \u00b7 <a href=\"https:\/\/cleanpeptides.eu\/retatrutide-dosage-guide\/\">Retatrutid doseringsguide<\/a><\/p>\n<h2>Referencer<\/h2>\n<ol>\n<li>Garvey WT, et al. \u00abCoadministered Cagrilintide and Semaglutide in Overweight or Obesity.\u00bb N Engl J Med. 2025;393(7):635-647.<\/li>\n<li>Davies MJ, et al. \u00abCagrilintide-Semaglutide in Overweight\/Obesity and Type 2 Diabetes.\u00bb N Engl J Med. 2025;393(7):648-659.<\/li>\n<li>Lau DCW, et al. \u00abOnce-weekly cagrilintide for weight management: a Phase 2 trial.\u00bb Lancet. 2021;398(10317):2172.<\/li>\n<li>Enebo LB, et al. \u00abCagrilintide with semaglutide 2.4 mg: a Phase 1b trial.\u00bb Lancet. 2021;397(10286):1736-1748.<\/li>\n<li>Gabe MBN, et al. \u00abCagrilintide and QTc: a thorough QT study.\u00bb Diabetes Obes Metab. 2024;26(12):5805-5811.<\/li>\n<\/ol>\n\n    <div class=\"xs_social_share_widget xs_share_url after_content \t\tmain_content  wslu-style-1 wslu-share-box-shaped wslu-fill-colored wslu-none wslu-share-horizontal wslu-theme-font-no wslu-main_content\">\n\n\t\t\n        <ul>\n\t\t\t        <\/ul>\n    <\/div> \n","protected":false},"excerpt":{"rendered":"<p>Kun til forskningsform\u00e5l \u2014 ikke beregnet til menneskelig brug. Clean Peptides giver ingen r\u00e5dgivning om dosering eller brug. Denne guide [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-10273","page","type-page","status-publish","hentry"],"_hostinger_reach_plugin_has_subscription_block":false,"_hostinger_reach_plugin_is_elementor":false,"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/pages\/10273","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/comments?post=10273"}],"version-history":[{"count":0,"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/pages\/10273\/revisions"}],"wp:attachment":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/media?parent=10273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}